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Tisagenlecleucel (tisa- cel) is a second- generation autologous CD19- targeted chimeric 
antigen receptor (CAR) T- cell therapy approved for relapsed/refractory (R/R) large 
B- cell lymphoma (LBCL). The approval was based on the results of phase II JULIET 
trial, with a best overall response rate (ORR) and complete response (CR) rate in in-
fused patients of 52% and 40%, respectively. We report outcomes with tisa- cel in the 
standard- of- care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL 
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1 |  INTRODUCTION
First- line immunochemotherapy cures around 60% of pa-
tients with large B- cell lymphoma (LBCL).1,2 In the relapse/
refractory (R/R) setting, second- line immunochemotherapy, 
usually including autologous stem cell transplant consolida-
tion, salvages less than half of the patients,3- 6 whereas those 
in the third- line setting have a dismal prognosis.7
Chimeric antigen receptor (CAR) T- cell therapy provides 
long- term remissions in a proportion of patients with R/R 
LBCL with significant but manageable toxicity. The results 
of two pivotal phase 2 clinical trials led to the approval of axi-
cabtagene ciloleucel (axi- cel) and tisagenlecleucel (tisa- cel) 
by the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for patients with R/R LBCL after 
2 or more lines of systemic therapy. These trials had strict in-
clusion criteria and infused around 100 patients each, mainly 
in United States (US).8- 10 Thus, evaluating the feasibility of 
this therapy outside the US, as well as gaining knowledge on 
the outcome of patients treated in the commercial setting is 
mandatory.
Several single- center and registry- based studies have 
shown that treatment with axi- cel is feasible outside the clin-
ical trial setting with a similar safety and efficacy profile 
to the pivotal trial.11- 14 However, data regarding the use of 
tisa- cel in patients with R/R LBCL outside clinical trials are 
scarce.13- 15
To provide valuable information on patient outcomes 
with commercial tisa- cel in LBCL, we performed a national, 
multicenter, retrospective study evaluating the safety and ef-
ficacy of tisa- cel in a European real- life setting.
2 |  METHODS
2.1 | Data collection and analysis
Data were collected retrospectively on all consecutive pa-
tients with R/R LBCL who underwent leukapheresis with 
the intent to manufacture commercial tisa- cel at 10 Spanish 
institutions from December 1st, 2018, until June 1st, 2020.
For the safety analysis, we included all patients who re-
ceived a tisa- cel infusion and had a minimum follow- up of 
1 month. Efficacy- evaluable patients included those who met 
the prior criteria and had an imaging response assessment. 
Survival outcomes were assessed in all patients who un-
derwent leukapheresis (intention- to- treat analysis, ITT) and 
in patients who received a CAR T- cell infusion. The study 
was approved by the ethics committee of the Vall d’Hebron 
Hospital Board.
2.2 | Patient management
Patients were selected by hematologists around the coun-
try when they met technical data sheet criteria. A checklist 
with the usual screening tests (PET scan, laboratory results, 
echocardiogram, repeat biopsy if applicable) was forwarded 
to the Spanish Ministry of Health, who reviewed the pro-
posal. Once it received approval, apheresis was performed. 
Bridging treatment was usually carried out at the local 
hospital.
Lymphodepleting (LD) chemotherapy included three 
consecutive days of fludarabine (25  mg/m2/day) and 
who underwent leukapheresis from December 2018 until June 2020 with the intent 
to receive SOC tisa- cel were retrospectively collected at 10 Spanish institutions. 
Toxicities were graded according to ASTCT criteria and responses were assessed 
as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 
(82%) received tisa- cel therapy. Grade 3 or higher cytokine release syndrome and 
neurotoxicity occurred in 5% and 1%, respectively; non- relapse mortality was 4%. 
Among the infused patients, best ORR and CR were 60% and 32%, respectively, with 
a median duration of response of 8.9 months. With a median follow- up of 14.1 months 
from CAR T- cell infusion, median progression- free survival and overall survival 
were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first 
disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate 
dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment 
with tisa- cel for patients with relapsed/refractory LBCL in a European SOC setting 
showed a manageable safety profile and durable complete responses.
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cyclophosphamide (250 mg/m2/day) in all cases and started 
once tisa- cel had arrived on site; if the CAR T- cell product 
did not meet commercial release criteria according to EMA 
requirements (out- of- specification, OOS) but it was consid-
ered acceptable by the physician, patients were offered treat-
ment through an expanded access protocol and their results 
were included. After 2– 4 days of chemotherapy washout, pa-
tients received the CAR T- cell infusion in a hospitalization 
regimen to guarantee a close monitoring of adverse events, 
such as cytokine release syndrome (CRS) and immune ef-
fector cell- associated neurotoxicity syndrome (ICANS). 
Management of these adverse events was carried out accord-
ing to the institutional guidelines in each center. Infectious 
complications were managed homogenously according to the 
Spanish consensus guidelines.16
For the efficacy analysis, all patients underwent a baseline 
Positron Emission Tomography and Computed Tomography 
(PET/CT) scan immediately before the start of LD chemo-
therapy (after the last bridging regimen) at the infusing center. 
Disease evaluation after CAR T- cell therapy was scheduled 
at 1, 3, 6, 12, 18, and 24 months after infusion. The imaging 
reports were based on the Lugano recommendation for re-
sponse assessment,17 and PET images were graded according 
to the 5- point Deauville score.
2.3 | Definitions and endpoints
Disease status at leukapheresis was defined as one of three 
possibilities: (a) primary refractory if never achieving end- 
of- treatment CR; (b) refractory to last therapy if not pri-
mary refractory but not achieving a complete response to 
the most recent therapy, (c) or relapsed. Bridging therapy 
was defined as any lymphoma- specific treatment admin-
istered after leukapheresis and before lymphodepleting 
chemotherapy.
Grading of CRS and ICANS was performed following the 
American Society for Transplantation and Cellular Therapy 
(ASTCT) criteria.18 Patients who were infused before April 
2019 were graded according to the Lee criteria19 and then 
re- assessed retrospectively to meet the 2019 criteria. Severe 
CRS and/or ICANS were defined as grade 3 or higher 
events. For the reporting of other adverse events, Common 
Terminology Criteria for Adverse Events (CTCAE) version 
5.0 was used.20 Tumor lysis syndrome was defined according 
to Cairo- Bishop criteria.21
Objective response rate (ORR) was defined as the per-
centage of patients who achieved a partial remission (PR) 
or complete remission (CR) after CAR T- cell infusion. 
Progression- free survival (PFS) was defined as the time from 
apheresis (ITT population) or CAR T- cell infusion until re-
lapse, progression, or death from any cause. Overall survival 
(OS) was defined as the time from apheresis (ITT) or CAR 
T- cell infusion until death of any cause. The duration of re-
sponse (DOR) was defined as the time from CR or PR to 
relapse, progression, or death from any cause, whichever oc-
curred first.
2.4 | Statistical analyses
A descriptive analysis of all included variables in the study 
was performed. Continuous variables were expressed as 
median and interquartile range (IQR), and categorical vari-
ables were expressed as absolute values and percentages. 
Univariate logistic regression model was carried out to es-
timate the association between ORR and baseline factors. 
Survival analysis (PFS and OS) was calculated using the 
Kaplan– Meier method and the log- rank test was used for 
statistical comparison. Cox proportional hazard models were 
used to obtain hazard ratios (HRs) with 95% CIs. For variable 
selection in multivariate analysis, we used the least absolute 
shrinkage and selection operator (LASSO) method to con-
struct the most parsimonious model.22 To assess the impor-
tance of the type of response at first evaluation, a landmark 
analysis using the date of first evaluation in non- progressor 
patients was performed.23
The data analyses were carried out using R statistical soft-
ware version 3.6.2.
3 |  RESULTS
3.1 | Patients and product characteristics
Ninety- one patients with R/R LBCL underwent leukaphere-
sis for tisa- cel. Seventy- five (82%) patients received the CAR 
T- cell infusion, whereas 16 (18%) did not. Reasons to not 
receive the infusion were: progressive disease (n = 11, 69%), 
manufacturing failure (n = 4, 25%), and psychiatric disorder 
(n = 1, 6%). All 75 patients had at least the first disease re-
sponse evaluation at 1- month post- infusion.
Baseline characteristics of the infused patients are sum-
marized in Table 1. The median age was 60 years (IQR 52– 
67) and 59% were male patients. Most had an International 
Prognostic Index score >2 (62%), an advanced stage (92%) 
and were primary refractory (52%). Sixty- five patients (87%) 
received bridging therapy before infusion, including chemo-
therapy in most cases (n = 56, 86%). The median time from 
apheresis to infusion was 53 days (IQR 49– 56). Median in-
fused cell dose was 3.5 × 108 CAR positive viable T- cells 
(IQR 1.5– 4.2). Eight products were considered OOS accord-
ing to EMA requirements and four could not be manufactured. 
Reasons for OOS were low cellularity (n = 6, 75%) and low 
viability (n = 2, 25%). Six of the eight OOS products were in-
fused (Table S1), the other two patients were not infused due 
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to rapid disease progression. Median follow- up from CAR 
T- cell infusion was 14.1 months (95%CI 13.1– 17.4).
3.2 | Safety analysis
Among the infused patients, 53 (71%) developed any grade 
of CRS; 21 (28%) and four (5%) patients developed grade 
≥2 and grade ≥3 CRS, respectively. Eleven (15%) patients 
developed any grade of ICANS, whereas five (7%) and one 
(1%) developed grade ≥2 and grade ≥3 ICANS, respectively. 
The median time from infusion to the onset of symptoms of 
CRS and ICANS was 2 days (IQR 1– 4) and 7 days (IQR 5– 9), 
respectively. Tocilizumab and steroids were administered to 
24 (32%) and 16 (21%) patients, respectively. Ten (13%) pa-
tients required admission to the Intensive Care Unit. By day 
90 post- infusion, three (4%) patients experienced treatment- 
related mortality: two from bacterial infection, specifically 
one case of Klebsiella pneumoniae BLEE sepsis and another 
of multiresistant Pseudomonas aeruginosa soft tissue infec-
tion (at 26 and 30 days from infusion, respectively) and one 
from macrophage activation syndrome (MAS)24 (at 36 days 
from infusion), despite treatment with tocilizumab, steroids, 
anakinra, and siltuximab. There were two other cases of 
MAS: one resolved with dexamethasone and the other with-
out specific treatment. Other adverse events including infec-
tion and tumor lysis syndrome are summarized in Table 2.
The univariate analysis of risk factors for the development 
of adverse events is summarized in Table S2. The baseline 
characteristics associated with an increased risk of grade ≥2 
T A B L E  1  Baseline characteristics of infused patients
Baseline characteristics of infused patientsa N = 75
Median age (IQR) - years 60 (52– 67)
Age ≥65 y– n (%) 23 (31)
Gender – n (%)
Male 44 (59)
Female 31 (41)
ECOG score, median (IQR) 1 (0– 1)
0– n (%) 25 (33)
1– n (%) 41 (55)
2– n (%) 5 (7)
Missing data – n (%) 4 (5)
Histology – n (%)
Diffuse large B- cell lymphoma, NOS 44 (58)
High grade B- cell lymphoma DH/TH 11 (15)
Transformed from follicular lymphoma 17 (23)
Transformed from other indolent histology 3 (4)
Cell of origin – n (%)
GCB 44 (59)
Non- GCB 24 (32)
Missing data 7 (9)
Disease stage- n (%)
Stage I- II 6 (8)
Stage III- IV 69 (92)
Extranodal disease (≥1 site)– n (%) 60 (80)
Bulky disease (>7 cm)– n (%) 30 (42)
LDH levels before treatment
<2xULN 51 (68)
≥2xULN 24 (32)
IPI prognostic score – n (%)
0– 2 25 (33)
3– 5 46 (62)
Missing data 4 (5)
Number of previous lines of treatment, median 
(IQR)
3 (2– 4)
2– 3 54 (72)
>3 21 (28)
 Previous ASCT – n (%) 29 (39)
Response to previous therapy – n (%)
Primary refractory 39 (52)
Refractory to last therapy 22 (29)
Relapsed 14 (19)
Bridging treatment - n (%) 65 (87)
Cyclophosphamide- Prednisone/CVPb 29 (44)
Platinum- basedc 16 (24)
Bendamustine- basedd 5 (8)
(Continues)
Baseline characteristics of infused patientsa N = 75
Rituximab- CHOPe 3 (5)
Steroids 2 (3)
Radiotherapy 2 (3)
Rituximab- Lenalidomide 2 (3)
Other chemotherapyf 3 (5)
Data not available 3 (5)
Abbreviations: ASCT, Autologous Stem Cell Transplant; DH/TH, Double Hit/
Triple Hit; ECOG, Eastern Cooperative Oncology Group; GCB, Germinal Center 
B- cell; IPI, International Prognostic Index; IQR, Interquartile range; LDH, Lactate 
Dehydrogenase; NOS, Not Otherwise Specified; ULN, Upper Limit of Normal.
aECOG score was missing in four patients, IPI missing in four patients; Bulky 
data missing in two patients, extranodal missing in one patient.
bCVP, Cyclophosphamide, vincristine, and prednisolone.
cPlatinum- based strategies included R- GEMOX (12), R- GDP (3) and R- ESHAP (1).
dBendamustine based included Rituximab- Bendamustine with (2) or without (3) 
Polatuzumab.
eCHOP, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.
fOther chemotherapy included MINE (Mesna, Ifosfamide, Mitoxantrone, 
Etoposide), R- IE (rituximab, ifosfamide, and etoposide) and R- hyperCVAD 
(Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone).
TABLE 1 (Continued)
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CRS and/or ICANS were ECOG (≥1 vs. 0), primary refrac-
tory disease, lactate dehydrogenase (LDH) levels (>2xULN 
[(Upper Limit of Normal)] vs. <2xULN), and the infused cell 
dose per kg of body weight (0.01- units increase).
3.3 | Efficacy analysis
3.3.1 | Disease response
Among the 75 infused patients, the best response achieved 
was CR in 24 (32%) patients and PR in 21 (28%), with an 
ORR of 60%. In the ITT analysis, the best response achieved 
was CR in 26% (24/91) with an ORR of 49% (45/91). Patients 
who achieved a response (CR or PR) had a median duration 
of response of 8.9 months (95%CI 2.2– NA). Stable disease 
and progressive disease were the best response in 6 (8%) and 
24 (32%) patients, respectively. Of the six infused OOS prod-
ucts, two patients achieved a CR, one patient achieved a sta-
ble disease and eventually progressed, whereas three patients 
progressed at the first disease assessment (Table S1).
Regarding the patients who achieved an initial PR at the 
1- month disease assessment, five (5/25, 20%) converted to 
CR at 3 (2 patients), 6, 12, and 18 months, respectively; the 
other patients in PR progressed in the following 3 to 6 months 
(18/25, 72%), or were in a maintained PR at data cutoff (2/25, 
8%). Regarding the nine patients who achieved an initial SD, 
two patients converted to a CR at 6- and 18- months post- 
infusion, respectively, and one patient improved to a PR 
at 3  months post- infusion; one patient remained in SD at 
6 months post- infusion and the remaining five patients had 
progressed at data cutoff.
In the subgroup analysis, ORR was consistent across all 
baseline characteristics except for the International Prognostic 
Index (IPI) score (a high IPI [3– 5] showed a lower ORR [OR 
0.35, p = 0.05]) and a history of previous indolent lymphoma 
(OR 3.59, p = 0.04) (Figure 1). In the subgroup analysis for 
CR, patients with an ECOG of 0, an LDH <2xULN and a low 
IPI score had a significantly increased probability of achiev-
ing a CR (Figure S1). There was no significant difference 
in any of the efficacy endpoints for patients with high- grade 
B- cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 
rearrangements.
Patients who developed grade 2 or higher CRS or ICANS 
had a similar ORR (65% vs. 58%, p = 0.54) and OS in com-
parison to patients who did not develop grade 2 or higher ad-
verse events. There was no significant impact of tocilizumab 
or steroid use on the ORR (69% and 81%, respectively, p- 
values >0.1).
3.3.2 | Survival analysis
Median PFS and OS for all infused patients were 3 months 
(95%CI 2.6– 4.7) and 10.7 months (95%CI 7.4– NA), respec-
tively (Figure  2). The overall 6- month and 12- month PFS 
was 33.3% and 31.7%, respectively. Patients in CR and PR 
at first disease evaluation had a PFS at 12 months of 87% 
and 20% (p < 0.001) and OS of 93% and 39% (p < 0.001), 
respectively (Figure S2).
In the ITT analysis, median PFS and OS from apheresis 
were 4.6 months (95%CI 4.1– 6.9) and 11.1 months (95%CI 
7.9– NA), respectively (Figure S3).
In terms of PFS, patients who were primary refractory, 
had an ECOG of 1 or higher, a non- GCB cell of origin, 
T A B L E  2  Safety analysis of infused patients
Safety profile of infused patients N = 75
CRS
Any grade; n (%) 53 (71)
Grade ≥2; n (%) 21 (28)
Grade ≥3; n (%) 4 (5)
Time from infusion to start of CRS; median days 
(IQR)
2 (1– 4)
Duration CRS; median days (IQR) 4 (4– 6)
ICANS
Any grade; n (%) 11 (15)
Grade ≥2; n (%) 6 (8)
Grade ≥3; n (%) 1 (1)
Time from infusion to start of ICANS; median days 
(IQR)
7 (5– 9)
Duration ICANS; median days (IQR) 9 (3– 14)
ICU, n (%) 10 (13)
Tocilizumab
Patients; n (%) 24 (32)
Median number doses tocilizumab (IQR) 1 (1– 5)
Corticosteroids
Patients; n (%) 16 (21)
Duration steroids; median days (IQR) 11 (8– 
15)
Macrophage activation syndrome, n (%) 3 (4)
Infections in the first month after infusion






Tumor Lysis Syndrome, n (%) 2 (3)
Treatment- related mortality, n (%) 3 (4)
Abbreviations: Cytokine Release Syndrome (CRS); Immune Effector Associated 
Neurotoxicity Syndrome (ICANS); Intensive Care Unit (ICU); Interquartile 
range (IQR).
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high IPI score and high LDH levels (>2xULN) had a sig-
nificantly lower PFS in the univariate analysis (Table 3 and 
Figure  3). Primary refractory disease [HR: 2.24 (95%CI 
1.20– 4.18), p  =  0.01] and high LDH levels [HR: 2.18 
(95%CI 1.19– 3.99), p = 0.01] maintained the independent 
statistical significance in the multivariate model (Table 3).
For OS, patients who were primary refractory, had an 
ECOG of 1 or higher, high IPI score and high LDH levels 
were associated with a lower OS in the univariate analysis 
(Table 3 and Figure 3). In the multivariate analysis, ECOG 
[HR: 2.80 (95%CI 1.10– 7.11), p  =  0.03] and LDH levels 
[HR: 2.33 (95%CI 1.14– 4.76), p = 0.02] remained signifi-
cantly associated with OS (Table 3).
4 |  DISCUSSION
This is the largest study to date focused exclusively on pa-
tients with R/R LBCL treated with tisa- cel in the real- world 
setting. We have shown that CAR T- cell therapy with tisa- cel 
is feasible outside the US and has a similar safety and effi-
cacy profile to the pivotal clinical trial.9
In our study, 91 patients with R/R LBCL underwent leu-
kapheresis for commercial tisa- cel and 75 (82%) patients 
received an infusion. The median time from apheresis to 
infusion was similar to the registration trial9 (54  days vs. 
53 days) and in both studies most patients received bridg-
ing therapy (92% vs. 87%). This turnaround time is longer 
than the published real- world data with axi- cel and tisa- cel 
in the US11,12,15 but similar to previous tisa- cel reports from 
European centers.13,14 Reasons behind this delay would in-
clude limited referral experience, reduced number of man-
ufacturing slots, and few European facilities; this could 
have certainly played a role in the number of patients who 
dropped out due to disease progression and, even, in the final 
outcome of the infused patients. This bridging period has 
gradually improved with the increasing experience of refer-
ral sites and a growing number of European manufacturing 
facilities.
Eight products were considered OOS in our study, 
mainly due to low cellularity. Low viability, a larger prob-
lem in the US, was not as frequent, probably due to the 
lower EMA limit in comparison with the FDA (70% vs. 
80% respectively).15 In our study, 82% of the patients who 
underwent apheresis received an infusion; in the pivotal 
trial9 only 67% of enrolled patients received an infusion, 
possibly related to the stricter criteria and the different 
baseline characteristics, which included a smaller number 
F I G U R E  1  Subgroup analysis according to ORR for infused patients. Note: Overall response rate according to baseline patient and disease 
characteristics
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of transformed patients in comparison to our cohort (19% 
vs. 27%, respectively).
Focusing on the safety analysis, the incidence of severe 
adverse events, including both CRS (5%) and ICANS (1%), 
was lower than the JULIET trial (22% and 12%, respec-
tively), taking into account the usual caveats derived from 
different grading systems.25,26 Noteworthy, our results were 
similar to a recent real- world registry- based study includ-
ing patients with LBCL and acute lymphoblastic leukemia 
treated with tisa- cel in the US.15 Reasons behind this trend 
for a better safety profile in the standard- of- care setting 
compared with the clinical trial includes an increased use of 
tocilizumab and steroids13,15 and more experience in CAR 
T- cell management.27 Preliminary data from European cen-
ters seem to confirm this lower rate of severe adverse events 
in the commercial setting.13,28 The median time to onset of 
CRS and ICANS was similar between our study and the reg-
istration trial (2 vs. 3 days and 7 vs. 6 days, respectively). 
Patients with primary refractory disease, a higher infused 
cell dose per kg of body weight, an ECOG ≥1 and elevated 
LDH levels showed an increased risk of developing grade 2 
or higher adverse events. In line with the pivotal CAR T- cell 
trials,8,9 older age was not associated with an increased risk 
of grade ≥2 toxicity, suggesting this is a feasible treatment 
modality for elderly patients with R/R LBCL. There was 
a 4% of treatment- related mortality in this study; however, 
all three patients were in progressive disease at the time of 
these events so this could have played a role in the final 
outcome.
Efficacy results in our study were similar to the pivotal 
trial. Interestingly, 12- month PFS for patients who achieved 
a CR at first disease assessment was 87%, confirming that 
most patients in this subgroup will maintain their response 
over time. However, the PR to CR conversion rate was lower 
in our study than in the pivotal trial9 (20% vs. 54%). We also 
observed that patients with a SD or PD as the best response 
after CAR T- cell therapy represent a high- risk subgroup: the 
12- month OS was 14% for patients with PD/SD, in compar-
ison to 28% for patients with PR and 95% for patients with 
CR. Therefore, patients in CR after tisa- cel therapy seem to 
have a very good prognosis, with durable remissions in most 
cases; patients who achieve a PR should be closely monitored 
during the first 3 months, the highest- risk period, to look out 
for early signs of progression and start additional therapies as 
soon as needed.
Patients with high LDH levels had a worse outcome after 
treatment with tisa- cel. Other studies also identified LDH11 
and high tumor volume, measured on CT29 or PET scan,14,30 
as clear prognostic factors for disease response after CAR 
T- cell therapy. Patients with primary refractory disease also 
had a lower PFS and OS. In line with previous publications, 
we found no significant efficacy difference for HGBL pa-
tients. Taking all this into account, patients progressing after 
second- line therapy with low tumor burden, a good perfor-
mance status, and low LDH could potentially benefit most 
from this treatment.
There are some limitations to this study. The data were 
collected retrospectively and many of the baseline char-
acteristics were captured before apheresis. Also, disease 
evaluation was only available previous to lymphodepleting 
chemotherapy; thus, it was not possible to assess the impact 
of disease response to bridging treatment as a prognostic fac-
tor for the efficacy of CAR T- cell therapy. Longer follow- up 
is needed to confirm the long- term duration of complete re-
missions and safety after tisa- cel therapy.
To the best of our knowledge, this is the largest standard- 
of- care cohort of patients reported to date with tisa- cel for 
R/R LBCL in a European country. Our results confirm that 
F I G U R E  2  PFS (a) and OS (b) for all infused patients and for patients achieving CR at first disease assessment. Note: PFS and OS in infused 
patients and in patients achieving CR after CAR T- cell infusion
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treatment with tisa- cel in Europe is feasible and has similar 
results to the pivotal trial.
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